150 related articles for article (PubMed ID: 16060192)
1. [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours].
D'Amato A; Pezzoli F; Caterino S; Cavallini M; Balducci G; Bocchetti T; Ziparo V
Chir Ital; 2005; 57(4):509-14. PubMed ID: 16060192
[TBL] [Abstract][Full Text] [Related]
2. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
3. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
[TBL] [Abstract][Full Text] [Related]
5. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
8. Surgery for gastrointestinal stromal tumour in the post-imatinib era.
Neuhaus SJ; Clark MA; Hayes AJ; Thomas JM; Judson I
ANZ J Surg; 2005 Mar; 75(3):165-72. PubMed ID: 15777399
[TBL] [Abstract][Full Text] [Related]
9. Imatinib in gastrointestinal stromal tumors.
Bakshi CA; Jain RA; Sastry PS; Sainani AR; Advani SH
J Assoc Physicians India; 2004 May; 52():403-9. PubMed ID: 15656032
[TBL] [Abstract][Full Text] [Related]
10. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Pauwels P; Debiec-Rychter M; Stul M; De Wever I; Van Oosterom AT; Sciot R
Histopathology; 2005 Jul; 47(1):41-7. PubMed ID: 15982322
[TBL] [Abstract][Full Text] [Related]
11. [Surgical treatment of an advanced GIST the age of imatinib].
Fernández JA; Parrilla P
Cir Esp; 2009 Jul; 86(1):3-12. PubMed ID: 19539273
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
[TBL] [Abstract][Full Text] [Related]
13. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour.
Abdulkader I; Cameselle-Teijeiro J; Forteza J
Histopathology; 2005 Apr; 46(4):470-2. PubMed ID: 15810964
[No Abstract] [Full Text] [Related]
14. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
Catani M; De Milito R; Simi M
Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
[TBL] [Abstract][Full Text] [Related]
15. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
16. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
[No Abstract] [Full Text] [Related]
17. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
18. Gastric GISTs. Personal experience.
Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
[TBL] [Abstract][Full Text] [Related]
19. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
20. Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach.
Harrison ML; Goldstein D
Intern Med J; 2006 Jun; 36(6):367-77. PubMed ID: 16732863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
